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Maternal health services 
a b s t r a c t 
Background: There is suboptimal uptake of recommended maternal vaccines (pertussis and influenza) during 
pregnancy in the UK. The Covid-19 pandemic has impacted healthcare services, and potentially vaccine coverage, 
and brought the need for new vaccines to be tested and rolled out. 
Objectives: To explore: i) the impact of the Covid-19 pandemic on pregnant women’s access to, and attitudes 
towards, routine maternal vaccines and; ii) women’s attitudes towards testing Covid-19 vaccines on pregnant 
women and their personal willingness to take part in such a trial. 
Design: Qualitative interview study with pregnant women in the Bristol and surrounding area (UK). 
Methods: Semi-structured telephone/videoconference interviews were conducted (following a topic guide), tran- 
scribed verbatim and subjected to thematic analysis. 
Results: Thirty-one pregnant women (selected for demographic range) were interviewed in April/May 2020. 
Participants felt the pandemic had elevated the importance of routine maternal vaccines, though women were 
concerned about safety management around appointment attendance. Women were wary of receiving a new 
Covid-19 vaccine, with most perceiving it as riskier than Covid-19 itself. 
Conclusions: It is important to maximise the safety and efficiency of maternity appointments to encourage uptake 
of routine maternal vaccines, and to communicate this well. For pregnant women to gain a new vaccine or 
participate in a vaccine trial, they need to be convinced that the risk posed by the virus is greater than any risk 



































In the United Kingdom (UK), the routine maternal vaccines currently
ffered via the National Health Service (NHS) are pertussis (whooping
ough), recommended for all pregnant women to receive between 16-32
eeks’ gestation ( NHS, 2019 ), and influenza, recommended for women
regnant during the winter season (September to March) ( NHS, 2019a ,
019b ). These vaccines have been shown to be safe ( Donegan et al.,
014 , Naleway et al., 2014 ) and effective ( Amirthalingam et al., 2014 ,
unes and Madhi, 2018 ). However, UK coverage rates are suboptimal
ith overall uptake at 70% for pertussis ( Public Health England 2020 )
nd around 44% for influenza ( Public Health England 2020 ). Common
arriers to receiving vaccination in pregnancy are women’s concerns
round vaccine safety, lack of healthcare professional (HCP) recommen-
ation, access issues and conflicting advice ( Bisset and Paterson, 2018 ).Abbreviations: HCP, Healthcare professional; IMD, Index of multiple deprivation; 
nited Kingdom. 
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266-6138/© 2021 The Author(s). Published by Elsevier Ltd. This is an open access avidence suggests most women will accept prenatal vaccinations if rec-
mmended by a trusted HCP for their baby’s health and if they have
ood access ( Wilson et al., 2015 ). The pertussis vaccine is delivered in
rimary care or at the 20-week foetal anomaly scan in many UK mater-
ity services, while the influenza vaccine is mainly offered in primary
are and at some pharmacies. 
The Covid-19 pandemic hit the UK in early 2020, and social distanc-
ng measures implemented from March 2020 onwards affected services
cross the NHS, including major changes to maternity care ( Jardine et
l., 2020 ). It is unclear at present exactly how the changes impacted on
regnant women’s access to routine vaccines, though we saw an over-
ll reduction in UK pertussis coverage in pregnant women from March
020 compared to previous years ( Public Health England 2020 ). Covid-
9 also placed the topic of vaccines centre-stage, and public confidence
nd attitudes are core to the success of vaccine programmes ( Verger andNHS, National, Health Service; PiP Study, Pregnant in a Pandemic Study; UK, 
2021 
rticle under the CC BY license ( http://creativecommons.org/licenses/by/4.0/ ) 




















































































































ubé, 2020 ). It is unclear what impact the pandemic may have had on
regnant women’s attitudes towards their routine maternal vaccines. 
New vaccines for Covid-19 have been developed and are continu-
ng to be developed ( Tregoning et al., 2020 , Parker et al., 2020 ). Vac-
ines must be tested on the populations due to receive them. To date,
o Covid-19 vaccine clinical trial has specifically focused on pregnant
omen ( Craig et al., 2020 ), despite pregnant women being classed as
at increased risk of severe illness from the virus that causes Covid-19’
y the Centers for Disease Control and Prevention ( Control CfD, Pre-
ention. People with Certain Medical Conditions 2020 ) and as ‘clini-
ally vulnerable’ to Covid-19 in the UK ( National Health Service (NHS),
020 ). Inclusion of pregnant women in vaccine trials has been consis-
ently advocated – for example by the American College of Obstetrics
nd Gynecology ( Craig et al., 2020 ) and for Covid-19 vaccine testing
pecifically ( Kampmann, 2021 , Vora et al., 2020 ), not least because in
he pandemic context, the frontline healthcare workforce has a dispro-
ortionately high number of women who could become, or are, preg-
ant. 
We aimed to gain understanding of women’s perceptions and expe-
iences of these issues to guide policy and practice both for continuing
outine maternal vaccination and for introducing Covid-19 vaccines to
regnant women. At the time, no Covid-19 vaccines were available, tri-
ls were underway but pregnant women were routinely excluded from
hese. We only had evidence that a minority of pregnant women would
e willing to participate in vaccine trials generally ( Jaffe et al., 2020 ,
almer et al., 2016 ) though it was not known whether they would be
illing to participate in a Covid-19 vaccine trial specifically. 
. Methods 
.1. Aim 
The aims of the current study were to explore: i) the impact
f the Covid-19 pandemic on pregnant women’s access to, and atti-
udes towards, routine maternal vaccines (pertussis and influenza) and;
i) women’s attitudes towards testing Covid-19 vaccines on pregnant
omen and their personal willingness to take part in such a trial. 
.2. Design 
As part of the ‘Pregnant in a Pandemic’ (Pip) qualitative interview
tudy ( Anderson et al., 2021 ), this sub-study was designed to explore
regnant women’s experiences and attitudes around routine maternal
accines and future Covid-19 vaccine testing in the context of the pan-
emic in the UK. 
.3. Recruitment and sampling 
Eligible participants were pregnant women of any gestation, living
n Bristol, UK or the immediate surrounding counties, aged 18 years or
bove, able to read and speak English to a sufficient level to consent and
articipate. The recruitment and sampling methods for the Pip study are
resented in detail elsewhere ( Anderson et al., 2021 ). In brief, pregnant
omen were invited opportunistically to express interest in taking part
n a study on social distancing (via local news, University communi-
ations, social media and local radio). Respondents filled in an online
xpression of interest form including demographics. Purposive sampling
as applied (according to participant age, ethnicity, Index of Multiple
eprivation [IMD] derived from home postcode, gestation, and avoid-
ng over-representation of those with medical/nursing training) to select
 range of women for interview. Full informed consent was established
rior to interview. Participants were offered shopping vouchers for tak-
ng part. The aim was to recruit around 30 pregnant women, aiming for
ata saturation of key themes to answer the research question ( Shaw
t al., 2019 ). All participants were invited to answer extra questions on
accines at the end of the social distancing interviews. 2 .4. Data collection 
Semi-structured interviews were conducted remotely via tele-
hone/videoconference by authors who all have experience of qualita-
ive research applied to healthcare and a background in health psychol-
gy and/or maternity service research (EA, AB, JI, AD, ES). Interviews
ollowed a topic guide exploring social distancing in the pandemic, and
nterviewees were given the option of answering extra questions about
accines at the end. The questions were: How important do you think it
s to have vaccination in pregnancy against ’flu and whooping cough? Has
he pandemic changed your thoughts about the importance of vaccines dur-
ng pregnancy? Has the pandemic impacted whether you have had or been
ble to get these vaccines during pregnancy? Do you think that new vac-
ines being developed to protect against Covid-19 should be tested in preg-
ant women to see if they are safe and effective? Would you be willing to
ake the vaccine? These were designed to initiate conversations to ex-
lore the key study aims, and interviewers allowed flexibility for ex-
ra discussion and invited further comments at the end of the discus-
ion. Interviews were audio-recorded, professionally transcribed verba-
im and pseudonymized before being imported into NVivo 11 software
 Castleberry, 2012 ) for analysis, ensuring secure storage (encrypted/
assword-protected). 
.5. Analysis 
The data were analysed using thematic methods ( Braun and Clarke,
006 ) of building codes into themes and sub-themes using the process of
onstant comparison, facilitated by NVivo software. Themes were com-
ared within and across the sample and structured around the interview
uestions while also seeking inductive and cross-cutting themes from the
ata. Independent coding was conducted (EA and AB) and transcripts
ere then double coded (ES). Differences were resolved via team dis-
ussion to ensure robust analysis. 
. Results 
Ninety-five women expressed an interest in participation and pro-
ided basic demographic and contact details, of whom 83 were eligi-
le and 31 were selectively sampled aiming for demographic diversity
ccording to age, ethnicity, gestation and to avoid overrepresentation
f those with a medical/nursing background. Participant characteristics
re presented in Table 1 . Of the 31 women in the sample, 20 were prim-
parous (first time expectant mothers); the age range was 24-48 years
mean 33), at the time of interview gestation ranged from 10-39 weeks
mean 24). Every IMD level was represented and the ethnicity of our
ample was: 24 (77%) White British, 7 (23%) other ethnicites (1 White
uropean, 2 Asian, 1 Black, 3 mixed). Two had medical/nursing train-
ng. All interviews took place (via telephone/videoconference) between
4 April and 7 May 2020. While the vaccine questions were presented
s optional, no interview participant declined to answer them. 
An overview of the main themes identified is presented in Table 2
nd these are described in more detail below. 
.1. General attitude to routine maternal vaccines 
.1.1. It is “very important ” to have routine pregnancy vaccines 
Most women in this study felt it was “very important ” to have their
ecommended maternal vaccines (pertussis, and influenza in ‘flu season)
nd reported general pro-vaccination attitudes; “I believe in vaccines ”
ID83), “I am very pro vaccination ” (ID41). Reported reasons included
rust in NHS/healthcare professional advice generally, and many stated
hat “it protects the baby ” (e.g. ID17) and/or themselves. 
“if it’s one that is recommended by the NHS then there’s a good reason
for doing, so ” (ID31) 
“to protect myself and my baby ” (ID25) 
E. Anderson, A. Brigden, A. Davies et al. Midwifery 100 (2021) 103062 
Table 1 
Participant characteristics. 
Consent ID IMD (from home post-code) Gestation at time of interview ∗ (weeks) Current age ∗ (years) Do you have children already? ∗ ∗ 
01 9 25-27 30-34 No 
03 3 16-18 35-39 No 
05 1 28-31 30-34 No 
06 10 32-35 30-34 No 
09 7 10-12 35-39 Yes 
11 5 22-24 25-30 No 
13 6 28-31 30-34 No 
14 1 28-31 20-24 No 
17 2 36 + 25-29 No 
18 8 36 + 35-39 Yes 
19 4 19-21 25-32 No 
20 7 16-18 30-34 No 
21 5 36 + 30-34 No 
24 4 32-35 35-39 Yes 
25 2 22-24 30-34 Yes 
31 4 28-31 40 + Yes 
32 5 13-15 35-39 Yes 
37 3 19-21 25-33 No 
39 7 10-12 35-39 Yes 
40 9 10-12 20-24 No 
41 4 32-35 25-34 No 
45 2 14-20 30-34 Yes 
46 5 28-31 30-34 No 
53 2 19-21 40 + Yes 
54 4 32-35 30-34 No 
60 7 16-18 25-31 No 
62 6 10-12 35-39 No 
79 2 32-35 40 + Yes 
82 2 22-24 30-34 Yes 
83 7 14-20 35-39 No 
85 1 22-24 30-34 No 
∗ Participant data presented as a range to preserve anonymity. Individual ethnicity data not presented to preserve anonymity. 
∗ ∗ information collected during interview. All other demographic information in this table was collected within the expression of interest 
form to inform sample selection. 
Table 2 
Thematic analysis: Overview of themes. 
Main area of questioning Themes identified 
1) General attitude to routine maternal vaccines 1.1) It is “very important ” to have routine pregnancy vaccines; 
1.2) Lack of knowledge/awareness 
2) Impact of pandemic on attitudes towards routine maternal 
vaccines 
2.1) “Elevating the importance ”; 
2.2) “I thought they were important before and I still think they are ”
3) Impact of pandemic on access to routine maternal vaccines 3.1) No impact (so far); 
3.2) Safety management around the appointment; 
3.3) Access and communication issues around routine vaccines 
4) Should Covid-19 vaccines be tested on pregnant women? 4.1) “I think they should be tested on pregnant women (but I wouldn’t 
volunteer) ”; 
4.2) “That’s a really tough question ” – ethics of risk to the baby; 
4.3) “Hell no ”: Covid-19 vaccines should not be tested on pregnant women 
5) Personal willingness to participate in a Covid-19 vaccine trial 5.1) “I am not going to be a guinea pig ” – personal unwillingness to participate 
in a vaccine trial; 















One participant differentiated in her attitudes towards pertussis and
nfluenza vaccines in terms of protection of her baby versus of herself: 
“I would have the one that protects the baby […] I don’t think I would be
worried if I got the flu [….] because I feel I can fight things off. I don’t like
the idea of having loads of things if I don’t necessarily have to ” (ID62). 
There was evidence that several women were motivated by personal
xperiences of illness in themselves or in a child: 
“I’ve had flu, you feel like you’re dying ” (ID05) 
“I had whooping cough as a child and I wouldn’t wish it on anyone, so I
will be getting that ” (ID03) 3 “My son had flu when he was four and a half, and ended up in hospital
for a couple of night s ” (ID18) 
Other motivating factors mentioned in interviews included suscepti-
ility to illness during pregnancy, that being ill while pregnant or with a
ew-born baby would be harder, and one woman mentioned additional
ltruistic motives: 
“you are slightly more susceptible to flu-related things when you’re preg-
nant ” (ID24) 
“it is pretty essential to reduce any risks[…] because I wouldn’t want to
risk me becoming unwell which could affect the baby ” (ID14) 


















































































“it protects your child and also then any other children when your child
is born, it stops infections from spreading ” (ID19) 
.1.2. Lack of knowledge/awareness 
By contrast, two women commented that they lacked knowledge
bout vaccines offered in pregnancy, though both mentioned that they
ould accept what was recommended: 
“I didn’t really know too much about ” (ID01) 
“it is not something I have thought about ” (ID62) 
.2. Impact of pandemic on attitudes towards routine maternal vaccines 
.2.1. Elevating the importance 
When discussing the impact of the pandemic on their attitudes to-
ards routine maternal vaccines, many women made comments along
he lines of “it just shows how important they are ” (ID39), and while feel-
ng vaccines were always important, women reported that Covid-19: 
“heightens it and makes you more aware ” (ID40) 
“reinforces that they are important ” (ID14) 
“was elevating the importance of it. ” (ID13) 
One woman thought the influenza vaccine may help protect against
ovid-19, stating; 
“I feel as if that might build up your immune system more towards it. I
know they say it’s not like a ‘flu, but having that vaccine in place might
protect you a little bit mor e ” (ID17). 
.2.2. I thought they were important before and I still think they are 
Other women described that the pandemic had no impact on their
ttitudes because they had always seen vaccination as very important: 
“I feel exactly the same , I still feel they are important . ” (ID32); 
“I always thought they were important; it’s not really changed anything . ”
(ID19) 
“I thought they were important before and I still think they are . ” (ID54).
.3. Impact of pandemic on access to routine maternal vaccines 
.3.1. No impact (so far) 
Women with more advanced pregnancy at the time of interview re-
orted that the pandemic had not impacted their ability to gain the
accine, and they recognised their good fortune: 
“I had those vaccines before this all happened. ” (ID05) 
“luckily I got them all before everything hit the fan . ” (ID54). 
At least four women reported receiving their pertussis vaccine after
he pandemic had hit the UK: 
“I had whooping cough about three weeks ago, four weeks ago, whilst we
were in the middle of the pandemic. ” (ID06). 
Two women commented that the services were continuing to offer
ssential services, suggesting that these women perceived routine vac-
ines as basic needs: 
“I think they are really trying to do what’s needed basically ” (ID82) 
“I am getting all the basic stuff I need. ” (ID83) 
Those in earlier stages of pregnancy had not reached the timepoint
here vaccines were due, so were unsure of how access would be im-
acted: 
“I see my midwife in week 16 so I will ask her then. ” (ID32) 
“ I have to call my GP and say I need a whooping cough vaccination. SoI suppose it depends how easy it is, I don’t know ” (ID09). 
4 .3.2. Safety management around the appointment 
When describing receiving their vaccines, some women sponta-
eously mentioned social distancing measures taken for the appoint-
ent: 
“it was in full swing, all the social distancing and PPE and stuff, and it
was fine […] it was very quick, she did it and I was out ” (ID85) 
“I had to go to the GP for that [pertussis vaccine], but it was a first
morning appointment when there was no one else in the surgery ” (ID01).
There was evidence that the pandemic caused women to weigh up
he benefits of attending appointments versus the risk of Covid-19 expo-
ure generally, and specifically for vaccine appointments, for example,
ne woman (with comorbid health issues) commented: 
“I suppose I am trying to limit the number of times that I go to hospital
because attending there is a risk, so if I had to go just to get a vaccine I
probably wouldn’t have gone. But because I had to go and get a scan, I
was able to do it at the same time I did go, if that makes sense? ” (ID53)
.3.3. Access and communication issues around routine vaccines 
There was also evidence that some (at least 3) women had experi-
nced issues in obtaining their vaccines; 
“so when I went for my twenty-week (scan) I presumed that was what
was going to happen again, but it didn’t, and because I don’t know the
routine of it I just assumed that you didn’t do it at that point ” (ID01). 
This is the same participant who reported a lack of knowl-
dge/awareness of vaccines (presented above, along with ID62). Two
ore women reported communication issues around the influenza vac-
ine: 
“I wasn’t really given any information. ” (ID60) 
“never had information on flu vaccine or why you should have it ” (ID40)
One woman reported having to make a separate GP appointment for
er pertussis vaccine because, although it was offered at the twenty-
eek scan, 
“they ran really behind and we had to go ” (ID14) 
It was not clear that these delays or communication issues were
pecifically due to the pandemic. 
One woman reported being symptomatic at the time of her influenza
accine appointment, so had to delay for two weeks due to Covid-19
easures which ended after the March cut-off date for receiving it: 
“So yeah I’ve missed that one . ” (ID60). 
.4. Should Covid-19 vaccines be tested on pregnant women? 
Participants’ responses to the question of whether Covid-19 vaccines
hould be tested (generally) on pregnant women ranged from feeling it
s was important, to stating it should not be done, with some feeling
nsure either way mainly due to ethical/risk issues, as shown below. 
.4.1. “I think they should be tested on pregnant women (but I wouldn’t 
olunteer) ”
Many participants recognised the importance of testing Covid-19
accines on pregnant women, though most mentioned in the same sen-
ence their unwillingness to do this themselves (e.g. ID21, ID83, ID82,
D40) or that it would be “great if somebody would want to ” (ID09).
ost just stated it was generally important, or to see if it works, while
ne commented that it was important: 
“because pregnant women are vulnerable as well, because they have got
weaker immune systems ” (ID17). 






















































































Several participants answered with a positive, though less certain
Yes, I guess ” (ID24, ID18) while again (spontaneously) mentioning
heir personal unwillingness to be in a trial: 
“I guess they should be, but I personally wouldn’t want it ” (ID11). 
.4.2. “That’s a really tough question ” – ethics of risk to the baby 
When asked if Covid-19 vaccines should be tested on pregnant
omen generally, several participants commented along the lines of this
eing “a really tough question ” (ID39) or a “difficult one ” (ID41). It was
erceived as an especially challenging question because “there’s another
ife involved. ” (ID19), and many women felt they were “on the fence ”
ID41) or simply stated “I don’t know ” (ID18). Many described ethical
oncerns: 
“there’s an ethical side to it isn’t there, because if you’re testing it you
don’t potentially know what the effects could be so it could harm the
baby ” (ID39) 
“That’s a really hard question, because we need to know that they are
safe but it’s a risk, and it’s a risk not necessarily just to the woman but
also to the child who doesn’t get a say in it . ” (ID19) 
One participant expressed uncertainty but felt it was “very much down
o the mother ”, feeling that if there were women “of sound mind who are
ble to rationale the decision to take a vaccine as a test then I think that’s
p to them ” (ID25). One participant commented “maybe at a later stage ”,
fter tests had showed the vaccine was safe in healthy people and those
ith different conditions first (ID13). 
.4.3. “Hell no ”: Covid-19 vaccines should not be tested on pregnant 
omen 
Three women felt that Covid-19 vaccines should not be tested on
regnant women due to the risks. There was a sense that this was specif-
cally because it was so new, and side-effects were unknown: 
“No, I think there’s too much risk. I think most things aren’t tested on
pregnant women so I don’t see why they should test that on them either . ”
(ID32) 
“Hell no, no test on the general population first please ” (ID53) 
“No I don’t think they should be done on pregnant women, just because
you don’t know the side effects, you know nothing about it. ” (ID60). 
.5. Personal willingness to participate in a Covid-19 vaccine trial 
When asked directly about their personal willingness to take part in
 Covid-19 vaccine trial, the majority of participants were unwilling,
ome were unsure, and others cited conditions under which they would
onsider it, as outlined below. 
.5.1. “I am not going to be a guinea pig ”– personal unwillingness to 
articipate in a vaccine trial 
As we have seen, when asked whether Covid-19 vaccines should be
ested on pregnant women generally, women spontaneously commented
hat they would not be willing to take part in a vaccine trial themselves.
hen directly asked about their personal willingness, most participants
esponded similarly: 
“No, definitely not. ” (ID32) 
“I am not going to be a guinea pig ” (ID79) 
“without knowing what the testing processes are and what the risks are is
my automatic gut reaction to just say no. ” (ID19). 
Though recognising the importance of testing, women described
hemselves as risk-averse during pregnancy, preferring to keep them-
elves safe in other ways: 
“I would much rather social distance at this stage ” (ID46). 5 “I know it probably could help but you just you almost go into a bubble
shell to protect everything ” (ID01) 
Women cited the unknown safety to them and their baby of a new
accine as the main reason for personal unwillingness to take a trial
ovid-19 vaccine, as well as comments about lack of confidence due to
ts novelty: 
“I think it’s really unfair to ask because there’s just too much at stake,
there’s two lives that could be ruined or affected negatively, so no. ” (ID45)
“Yeah, I worry enough about having a miscarriage or something like that
just naturally, so I think adding a potential further risk factor would make
me think twice. ” (ID39) 
“it’s not the risk to myself, it’s the risk to my baby which would be a
potentially unknown, so that would be my reason. ” (ID25) 
“just because it’s so new [...] I wouldn’t have any confidence in it yet ”
(ID62). 
Personal experience fed into attitudes, with one woman not keen
ased on anecdotal adverse outcomes from another vaccine, while an-
ther mentioning having known babies born with Covid-19 who “have
een alright ” so she was more worried about the vaccine: 
“I would be more worried about the impact of a vaccine that hadn’t been
trialled properly, having long term impact than having to navigate getting
treatment if that makes sense? ” (ID54) 
“I have a friend that got really… she got ME and narcolepsy from the
swine flu vaccine, because that was developed pretty quickly I think as
well, and I think that’s just stuck with me ” (ID45) 
One woman alluded to the thalidomide tragedy ( Kim and Scialli,
011 ) and anxieties about the relative risks of vaccinating versus catch-
ng Covid-19, especially in the early stages, while another reported a
onversation she had with friends about signing up for a vaccine trial,
hich indicated strong fears based on her understanding of the vaccine:
“the early stages where the baby is really developing its body and brain
and everything […] So there’s the worry of both catching it, and then
there’s the worry of what a vaccination could do if it was the wrong
thing. ” (ID18) 
“we were just like no because basically you’re injecting coronavirus to see
if your body will create antibodies towards it, coronavirus kills people,
basically you’re signing your death certificate ” (ID05) 
By contrast, two women commented that they were simply unsure
bout whether they would personally be willing to take a new vaccine,
gain considering risks associated with pregnancy: 
“if I wasn’t pregnant I would definitely be up for taking part, it just feels
like a bit of a risk. I am not sure, I would need to think about that one. ”
(ID03) 
“would I be willing to take a vaccine? I don’t know is the answer […] we
just don’t know how it reacts, and pregnant women are a very vulnerable
group of the population ” (ID85). 
.5.2. Would consider taking part in a vaccine trial if…
Five women described conditions in which they would consider vol-
nteering for a Covid-19 vaccine trial, which centred on increased risk
f the virus to pregnant women, and more safety testing of the virus: 
Two commented that their willingness to volunteer may change if
heir perceived balance of risks changed: 
“if the illness was a lot more dangerous in pregnancy and I had a good
chance of getting it anyway and the vaccine looked like it was promising ”
(ID31). 
























































































































v  “In my age group the possibility of death is pretty low, if it was… for
example if I was facing the possibility of death of an 80-year-old, if the
virus changes if it’s one out of two people could die from this, if the virus
adapts or changes its structure then I may change my opinion on whether
I would try a new vaccine. Basically I don’t want to die and I don’t want
my husband to die and I don’t want my baby to come out weird. ” (ID83)
Three women reported a potential (though uncertain) willingness to
ake a vaccine within a trial while pregnant, or at least consider it, only
f a certain amount, or type, of prior testing had already been completed:
“if we’re talking two years down the line and then pregnant again and
there’s been multiple trials, so in that hypothetical example and like I say
it’s been well tested but it’s just we’re just looking at a test for pregnant
women I would consider it then, but definitely not at this early stage. ”
(ID13). 
“perhaps if they had done really in-depth preclinical studies and they had
shown no side effects in ovulating women and maybe pregnant primates
or something like that. ” (ID37). 
“if it was the end of the trial and they had already tested on hundreds of
other pregnant women and there had been no reported side effects at this
point and babies had been born healthy then possibly. But I would still be
quite nervous about it I think. ” (ID41). 
By contrast, two women reported a more active willingness to vol-
nteer for a vaccine trial while pregnant. One said: 
“I would be willing to be part of a phase II or a phase III clinical trial
knowing and having seen the data that had come beforehand . ” (ID06) 
The other focused on the risks of the vaccine equalling the risks of
ovid-19 (as the vaccine would be a form of the virus) as well as altru-
stic motives: 
“if you’re pregnant and you do get it you’re as likely as anyone else to
have not really bad symptoms if you don’t have any pre-existing other
conditions […] I am otherwise healthy and quite young, or youngish,
middle aged, so I guess I would feel fairly okay about having it myself.
So I would be willing to have the test and be part of that if it helped other
pregnant women, definitely ” (ID24) 
. Discussion 
This study is among the first to explore pregnant women’s percep-
ions of how the Covid-19 pandemic has impacted access to, and at-
itudes towards, routine maternal vaccines in the UK and to explore
regnant women’s views on participating in Covid-19 vaccine trials. In
he time since these interviews, Covid-19 vaccines have been developed
nd rolled out to the general population - from December 2020 in the
K, starting with the elderly and clinically vulnerable. Initially the vac-
ine was not recommended for pregnant women due to lack of evidence,
hough the UK guidance changed to advise pregnant women to consider
ccepting a Covid-19 vaccine if they were at high risk of infection (e.g.
orking as a healthcare professional) on one-by-one basis. The guidance
hanged again (on 16 April 2021) to recommend that pregnant women
ccept the vaccine when invited with their age-cohort ( JCVI, 2021 ). Our
esults provide important considerations for communication to promote
accine uptake in pregnant women in this rapidly changing context. 
Routine vaccines: Risk-aversion characterised participants’ re-
ponses to all the questions in this study, echoing cultural and med-
cal conceptualisations of pregnancy as a time for women to be vigi-
ant of risks for the health of their baby ( Rothman, 2014 , Ballantyne et
l., 2016 ). Women in our sample mostly described themselves as ‘pro-
accine’ and felt that routine vaccines were very important, and even
ore so since the pandemic had hit, which aligns with early findings
hat Covid-19 strengthened positive attitudes towards vaccines in the
eneral population ( Blanchard-Rohner et al., 2020 ). Because of the tim-
ng of interviews (April/May 2020), and the timing of the pandemic6 ffecting services (March onwards), most comments on access to rou-
ine vaccines centred on pertussis, as influenza is administered season-
lly (September to March). We found some evidence of difficulties in
btaining routine vaccines, and of a lack of knowledge/communication
bout maternal vaccines, though it was not clear if this was due to the
andemic or to pre-existing service issues. Despite recognising the im-
ortance of vaccines, the safety of attending for appointments was an
mportant concern for these women when discussing vaccines (as pre-
ented) and maternal appointments generally (as presented elsewhere
 Anderson et al., 2021 )). We know that any barriers to vaccine access
egatively affect uptake ( Bisset and Paterson, 2018 ). Our findings align
ith evidence of disruption to pregnancy vaccination programmes inter-
ationally – largely due to access issues and user concerns about safety
f attending appointments ( Saso et al., 2020 , Ceulemans et al., 2021 )
s well as evidence of comparable pandemic-related barriers to infant
accination in the UK ( Bell et al., 2020 ). Concern around the safety of
ttending appointments is a new barrier introduced by the Covid-19
ontext, which requires careful consideration by services if we are to
aintain routine vaccine coverage and minimise the risks of vaccine-
reventable illness. 
Covid-19 vaccines: Most women expressed unwillingness to be a
guinea pig’ in Covid-19 vaccine trials, voicing fears about unknown ef-
ects of a new vaccine. Concerns centred on the risks of a vaccine (to
hemselves and their unborn baby), and women tended to view risks
ssociated with a new vaccine as greater than that posed by Covid-19
tself. Some women identified conditions under which they would con-
ider volunteering for a vaccine trial, centring on perceptions of illness
isk and knowledge of vaccine safety. This is similar reasoning presented
onversely to recommend that Covid-19 vaccines should not be withheld
rom pregnant women, but considered on an individual risk-benefit pro-
le accounting for risk of exposure, health status and risk of Covid-19-
elated complications ( Craig et al., 2020 ). The reluctance of the women
e interviewed to accept a (hypothetical at the time) Covid-19 vac-
ine aligns with the findings of surveys indicating greater reluctance
o accept a Covid-19 vaccine in pregnant women (compared with non-
regnant women) in the UK and internationally with key reasons being
otential harms to the foetus and a desire for more evidence of safety
nd efficacy ( Ceulemans et al., 2021 , Skjefte et al., 2021 , Skirrow et
l., 2021 , Goncu Ayhan et al., 2021 ). Interestingly, the study in Turkey
ound greater Covid-19 vaccine acceptance for the first trimester by con-
rast to our findings where women expressed more wariness about being
accinated early in the pregnancy ( Goncu Ayhan et al., 2021 ). 
The strengths of this study are its novelty and relevance to the cur-
ent and shifting pandemic context, the application of robust qualitative
ethods and maximum diversity sampling. One limitation is that partic-
pants in our sample were relatively homogenous in their ‘pro-vaccine’
iews, and comments within interviews indicated that there may have
een over-representation of university employees, though diversity ac-
ording to key demographics was achieved. Our results may therefore
nder-represent the vaccine hesitancy at play in the wider population,
hough even in this pro-vaccine population, we have demonstrated how
ovid-19 safety concerns can be a barrier to gaining routine vaccines
nd that pregnant women are very wary of receiving a new vaccine. 
Interviews were conducted within one two-week period at the be-
inning of the first UK lockdown. Comments concerned a hypothetical
ovid-19 vaccine. Research has shown that healthcare professionals’
illingness to accept a Covid-19 vaccine was higher after announce-
ents of vaccine efficacy and authorisation of their use than prior to
his when the question was about a hypothetical vaccine ( Meyer et al.,
020 ). While it is possible that the authorisation and roll-out of new
ovid-19 vaccines may have similarly shifted pregnant women’s atti-
udes, a key difference is that efficacy and safety data have been missing
or pregnant women due to their exclusion from Covid-19 vaccine trials
o date. 
While the evidence remains limited, we are now starting to see rele-
ant safety and efficacy data related to Covid-19 infection and Covid-19














































































































accines in pregnancy, which may affect women’s attitudes. A system-
tic review found that Covid-19 infection was associated with increased
isks of pre-eclampsia, pre-term birth and other adverse pregnancy out-
omes ( Wei et al., 2021 ). Gray et al ( Gray et al., 2021 ) found that vacci-
ating pregnant women conferred robust maternal and neonatal immu-
ity to Covid-19. A US study found no evidence of safety concerns for
regnant women receiving mRNA Covid-19 vaccines, though advised
hat more research is needed ( Shimabukuro et al., 2021 ). Communicat-
ng such evidence of safety and effectiveness appropriately to pregnant
omen is vital. 
The timing of interviews also meant that many women in this study
ad either received their routine vaccines prior to any service disrup-
ion or had not yet reached the timepoint when vaccines were due, so
outine vaccine access issues were mostly unknown. Evidence of declin-
ng pertussis vaccine coverage in pregnant women since March 2020
 Public Health England 2020 ) and early evidence that the pandemic
egatively impacted women’s access to maternal (and infant) vaccines
nternationally ( Saso et al., 2020 ) suggests there are systemic problems
o be addressed. Future research should explore in more detail the full
mpact of the pandemic on women’s access to routine maternal vaccines
n the UK and what can be done to improve the situation at the service
evel. 
. Conclusions / Implications for policy and practice 
Routine vaccination must remain a priority to avoid undoing years
f progress on vaccine coverage and facing resurgence of vaccine-
reventable disease ( Saxena et al., 2020 ). It is important to maximise
he safety and efficiency of maternity appointments during a pandemic
o minimise the burden on women of risk-based decision-making around
ppointments and to increase the likelihood of vaccination. In this con-
ext it is even more important that the pertussis vaccine is offered at the
oetal anomaly scan (approximately 20 weeks), or another important
ppointment, rather than women being required to make and attend a
eparate appointment solely for the vaccine. Access to influenza vaccines
or pregnant women should follow similar lines – being as safe and easy
o access as possible, reducing need for multiple appointments, along
ith good communication from healthcare providers. 
Pregnancy is a time when women are expected to mitigate risk to
hemselves and their babies ( Ballantyne et al., 2016 ), which was evi-
ent in this study. In this context, pregnant women are less likely than
he general population to volunteer to accept a new vaccine and they
eed evidence of extensive safety-testing at least on the general popu-
ation first. The changing policy and communication efforts which are
ow recommending Covid-19 vaccination in pregnancy must continue
o address women’s fears by presenting clear, unequivocal evidence to
xplain the rapid development of the vaccine and how it safely confers
mmunity. Continued research into vaccine safety and efficacy for preg-
ant populations is absolutely vital and the results must be scrutinised
nd well-communicated. The exclusion of pregnant women from vaccine
rials is a key concern for gender-based equity of healthcare as it leaves
omen and healthcare workers without the necessary evidence to make
 decision about vaccination. We need to prioritise the best way to in-
lude pregnant women in future vaccine trials rather than exclude them
y default. For vaccine acceptance generally, pregnant women need to
now that the risk posed by the virus is greater than any risk of receiving
he new vaccine. 
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